Unacom Pharma News
Nigel Cook, Head of Decision Support and Insights, Global Patient Access at Novartis said: “ The scientific advice provided by NICE, together with the patient representative and other external experts, has been very valuable to Novartis; both in endorsing the approach to gathering early patient preference data to inform evidence generation plans, and in regard to valuable input received to improve the design of the COPD patient preference study.
There have been concerns that NICE’s fee-based approach for technology appraisals could compromise integrity and their decision making. NICE has since clarified that paying for scientific advice has no bearing on tech appraisals and will not make a positive recommendation more likely.
Thursday 14th February.
Europe's first medicine tracking system goes live.
The new worlds first digital tracking system covering the medicine supply chain across the EU has gone live, promising greater security against counterfeit medicines. The new European Medicines Verification System (EMVS) is a world first and uses a 2D data matrix (barcode) to track every pack of medicines as they make their way from the manufacturer into the supply chain and on to the patient. The medicines also now have anti-tamper device (ATD) to ensure they are not interfered with before the patient receives them. This system aims to prevent the occurrence of fake drugs entering the supply chain, which has quickly become a multi-million pound industry.
The EMVS will connect around 2,000 pharmaceutical companies, around 6,000 wholesale distribution authorization holders, 140,000 pharmacies, 5,000 hospital pharmacies and around 2,000 dispensing doctors in 28 EEA countries.
The UK pharma industry and NICE welcomed the new system, praising it as the ‘world’s best’ medicines safety system and that it would be a travesty if the UK had to leave the system because of a no deal Brexit.
Friday 15th February
The potential in AI predicting survival of Ovarian Cancer Patients.
Researchers from Imperial College London have created an AI software that can predict the survival rates and responses to treatments of patients with ovarian cancer. Researchers say that this new tech could help clinicians administer the best/most effective treatment to patients faster and pave the way for more personalized medicines. AI has the huge potential to revolutionize the healthcare industry by offering more accurate and earlier diagnoses, transforming the lives of the patients.